GSK (LON:GSK) Stock Rating Reaffirmed by Deutsche Bank Aktiengesellschaft

GSK (LON:GSKGet Rating)‘s stock had its “hold” rating reissued by research analysts at Deutsche Bank Aktiengesellschaft in a research report issued to clients and investors on Wednesday, Marketbeat reports. They presently have a GBX 1,500 ($17.63) price objective on the stock. Deutsche Bank Aktiengesellschaft’s target price would suggest a potential upside of 10.75% from the stock’s previous close.

A number of other equities research analysts have also recently commented on GSK. Berenberg Bank lowered their price objective on shares of GSK from GBX 1,950 ($22.91) to GBX 1,580 ($18.57) and set a “buy” rating on the stock in a research note on Wednesday, September 14th. Shore Capital reissued a “buy” rating on shares of GSK in a research note on Wednesday, November 2nd. JPMorgan Chase & Co. lowered their price objective on shares of GSK from GBX 1,900 ($22.33) to GBX 1,600 ($18.80) and set a “neutral” rating on the stock in a research note on Tuesday, November 8th. Citigroup reissued a “neutral” rating and issued a GBX 1,975 ($23.21) price objective on shares of GSK in a research note on Thursday, July 21st. Finally, UBS Group set a GBX 1,300 ($15.28) price target on shares of GSK in a research note on Friday, November 11th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of GBX 1,622 ($19.06).

GSK Price Performance

Shares of LON GSK opened at GBX 1,354.40 ($15.92) on Wednesday. The stock has a market cap of £55.09 billion and a price-to-earnings ratio of 1,242.57. GSK has a 52 week low of GBX 1,280.92 ($15.05) and a 52 week high of GBX 1,824.40 ($21.44). The company’s 50-day moving average price is GBX 1,360.30 and its 200 day moving average price is GBX 1,553.04. The company has a current ratio of 0.97, a quick ratio of 0.73 and a debt-to-equity ratio of 253.74.

Insider Buying and Selling

In related news, insider Jonathan Symonds bought 3,220 shares of the firm’s stock in a transaction that occurred on Thursday, September 29th. The shares were acquired at an average cost of GBX 1,324 ($15.56) per share, with a total value of £42,632.80 ($50,097.30). Over the last three months, insiders have purchased 3,237 shares of company stock valued at $4,286,706.

GSK Company Profile

(Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

See Also

Analyst Recommendations for GSK (LON:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with's FREE daily email newsletter.